CoChat

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht088

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page

Cited by

See all 99

Metadata

Authors
Norata, G. D., Ballantyne, C. M., & Catapano, A. L.
Affiliations
  • Queen Mary University of London (GB)
  • Houston Methodist (US)
  • University of Milan (IT)
Corresponding author
Catapano, Alberico Luigi
Venue
European Heart Journal
Published
2013-03-18
Volume
34
Issue
24
Pages
1783-1789
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2170662336
Cited by
99
References
53
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 13 · 2016: 13 · 2015: 16 · 2014: 19 · 2013: 5
FWCI
3.12
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eSpace (Curtin University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • American Heart Association
  • Bristol-Myers Squibb
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Amarin Corporation
  • National Institutes of Health
  • Genentech
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
dyslipidemia, LDL cholesterol lowering, lipoprotein(a), PCSK9 inhibitors, apolipoprotein B, non-HDL cholesterol, statins, combination lipid-lowering therapy, cardiovascular risk, atherogenic lipoproteins
MeSH terms
Ezetimibe, Proprotein Convertase 9, Hypolipidemic Agents, Azetidines, Benzimidazoles, Benzodiazepines, Carrier Proteins, Dicarboxylic Acids, Fatty Acids, Humans, Cholesterol, LDL, Oligonucleotides, Serine Endopeptidases, Lipoprotein(a), Oxazolidinones, Proprotein Convertases, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. https://app.cochat.ai/papers/10.1093/eurheartj/eht088
The paper
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013). New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal. https://doi.org/10.1093/eurheartj/eht088

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.